{"id":"W4290879625","doi":"10.1200/jco.21.02815","title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Internal medicine; Dexamethasone; Refractory (planetary science); Clinical endpoint; Multiple myeloma; Hazard ratio; Ixazomib; Progression-free survival; Oncology; Surgery; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01298468,0.0002653965,0.003939121,0.0002734997,0.0004745435,0.000027498,0.0003421758,0.0002685036,0.0008276497],"category_scores_gemma":[0.02624278,0.0001588411,0.002274047,0.0003116007,0.0004570693,0.0001093177,0.000289212,0.00161665,0.000003280087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005049942,"about_ca_system_score_gemma":0.002390516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005421002,"about_ca_topic_score_gemma":0.0001781628,"domain_scores_codex":[0.9907555,0.004320908,0.003042625,0.0004268579,0.0009838325,0.0004702893],"domain_scores_gemma":[0.9489982,0.04722657,0.00234612,0.0004072955,0.000382636,0.0006391811],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9234996,0.006278227,0.004796439,0.000007569386,0.01185467,0.0007670277,0.0002603142,0.00005856963,0.00007831924,0.00008482899,0.001782844,0.05053162],"study_design_scores_gemma":[0.9021695,0.03599601,0.01720917,0.00001416031,0.006775934,0.0000821421,0.0002956259,0.004156029,0.00001245886,0.0004005932,0.03275205,0.0001363705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869807,0.001935522,0.001124294,0.006026139,0.001510273,0.001952489,0.0001769109,0.00001372675,0.000279958],"genre_scores_gemma":[0.9910064,0.000603134,0.004650307,0.000981144,0.001595352,0.0002081689,0.0001182189,0.00002992227,0.0008073156],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05039525,"threshold_uncertainty_score":0.9819596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1882167091889099,"score_gpt":0.47928399839735,"score_spread":0.2910672892084402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}